346 related articles for article (PubMed ID: 16343994)
1. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.
Judge AD; Bola G; Lee AC; MacLachlan I
Mol Ther; 2006 Mar; 13(3):494-505. PubMed ID: 16343994
[TBL] [Abstract][Full Text] [Related]
2. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.
Judge AD; Sood V; Shaw JR; Fang D; McClintock K; MacLachlan I
Nat Biotechnol; 2005 Apr; 23(4):457-62. PubMed ID: 15778705
[TBL] [Abstract][Full Text] [Related]
3. 2'-O-methyl-modified RNAs act as TLR7 antagonists.
Robbins M; Judge A; Liang L; McClintock K; Yaworski E; MacLachlan I
Mol Ther; 2007 Sep; 15(9):1663-9. PubMed ID: 17579574
[TBL] [Abstract][Full Text] [Related]
4. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
Morrissey DV; Blanchard K; Shaw L; Jensen K; Lockridge JA; Dickinson B; McSwiggen JA; Vargeese C; Bowman K; Shaffer CS; Polisky BA; Zinnen S
Hepatology; 2005 Jun; 41(6):1349-56. PubMed ID: 15880588
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs.
Shin D; Kim SI; Park M; Kim M
Biochem Biophys Res Commun; 2007 Dec; 364(3):436-42. PubMed ID: 17963721
[TBL] [Abstract][Full Text] [Related]
6. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
7. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
8. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
[TBL] [Abstract][Full Text] [Related]
9. Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA.
Gorina R; Santalucia T; Petegnief V; Ejarque-Ortiz A; Saura J; Planas AM
Glia; 2009 Jan; 57(1):93-107. PubMed ID: 18709661
[TBL] [Abstract][Full Text] [Related]
10. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
Bartlett DW; Davis ME
Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
[TBL] [Abstract][Full Text] [Related]
11. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
[TBL] [Abstract][Full Text] [Related]
12. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
[TBL] [Abstract][Full Text] [Related]
13. Profiling RNA interference (RNAi)-mediated toxicity in neural cultures for effective short interfering RNA design.
Read ML; Mir S; Spice R; Seabright RJ; Suggate EL; Ahmed Z; Berry M; Logan A
J Gene Med; 2009 Jun; 11(6):523-34. PubMed ID: 19322910
[TBL] [Abstract][Full Text] [Related]
14. siRNA binding proteins of microglial cells: PKR is an unanticipated ligand.
Zhang Z; Weinschenk T; Guo K; Schluesener HJ
J Cell Biochem; 2006 Apr; 97(6):1217-29. PubMed ID: 16315288
[TBL] [Abstract][Full Text] [Related]
15. Hydrodynamic delivery protocols.
Rychahou PG; Evers BM
Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
[TBL] [Abstract][Full Text] [Related]
16. Management of chronic hepatitis B virus infection: a promising approach using small interfering RNA (siRNA).
Dwivedi M; Misra SP; Misra V; Waikhom RK; Bhatnagar M
Natl Med J India; 2008; 21(3):123-7. PubMed ID: 19004143
[TBL] [Abstract][Full Text] [Related]
17. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
Takahashi Y; Nishikawa M; Takakura Y
Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
[TBL] [Abstract][Full Text] [Related]
18. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
[TBL] [Abstract][Full Text] [Related]
19. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
